Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (380)	10/29/1998 8:51:00 PM
From: Bull-like	Read Replies (1) \| Respond to of 642

Anthony, lilly is trying the 52-week high again. I doubt it will break the high, though. The market is pretty cautious. I think the real issue is if Lilly's evista can match the tamoxifen in terms of prevention of breast cancer. My gut feeling is that evista will eventually emerge as a better drug after the trial. Particularly less side effects. Although this could 2-3 years down the road. Given the current urgent, anything-goes, anti-cancer atmosphere in D.C., the process could be even faster than we think, for good or bad. Da bull